Digital An overview of AI in pharma – Part 2 According to Takeda Pharmaceuticals, the average time taken to diagnose a rare disease without technology is 7.6 years, and that comes after countless tests and physician visits.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.